Andrew Dickinson, the Chief Financial Officer of Gilead Sciences, Inc. (NASDAQ:GILD), recently executed a series of transactions involving the company's stock. On February 12, Dickinson sold 137,676 ...
Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.
It was a busy week for the biotech sector, as the fourth-quarter earnings season is in full swing. While Gilead Sciences, Inc ...
The aggregate gross proceeds to the Company from the offering were approximately $1,050,000, before deducting the placement ...
A look at the M&A and stock market pictures for full-year 2024—and the potential strategic implications for pharma and ...
Financing led by Velan Capital with participation from new and existing healthcare-focused institutional investors and ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Irhythm Technologies (IRTC – Research Report), Vir ...
Kingsview Wealth Management LLC lifted its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 60.3% during the ...
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at Chardan Capital in a research report issued on Tuesday,Benzinga reports.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback